I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EL/982743214 UB, in an envel-pe addressed to: MS AF, Commissioner for Patents, P.O. Box 1450, Aleyand

Dated: November 3, 2004 Signat

Docket No.: UMY-052

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Patent Application of:

Craig C. Mello et al.

Application No.: 09/689992

Confirmation No.: 1020

Filed: October 13, 2000

Art Unit: 1637

For: RNA INTERFERENCE PATHWAY GENES

AS TOOLS FOR TARGETED GENETIC

INTERFERENCE

Examiner: Teresa E. Strzelecka

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATION CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

MS AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

The U.S. Patent and Trademark Office has taken the position that the previous "Sequence Listing" in computer readable form did not comply with the requirements of Section 1.824 for the stated reason that it contained several raw sequence listing errors. Submitted herewith in connection with the above-referenced patent application is a substitute, computer readable copy of the Sequence Listing that corrects the defects noted in the raw sequence listing. No new matter has been added to the substitute Sequence Listing.

Applicants respectfully request the above-referenced patent application be placed upon the files for examination.

Application No.: 09/689992 Docket No.: UMY-052

Applicant believes no fee is due with this statement. However, if a fee is due, please charge our Deposit Account No. 12-0080, under Order No. UMY-052 from which the undersigned is authorized to draw.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. UMY-052.

Dated: November 3, 2004

Respectfully submitted.

Debra J. Milasincic, Esq.

Registration No.: 46,931

LAHIVE & COCKFIELD, LLP

28 State Street

Boston, Massachusetts 02109

(617) 227-7400

(617) 742-4214 (Fax)

Attorney/Agent For Applicant

OIFE	in the second se		
	Application No.	Applicant(s)	·
NOV 0 3 2004	09/689,992	MELLO ET AL.	
	Examiner	Art Unit	·
PADEMENT PADEMENT	Teresa E Strzelecka	1637	
NOTICE TO COMPLY WITH REQUIREM NUCLEOTIDE SEQUENCE AND/OR AM Applicant must file the items indicated below within avoid abandonment under 35 U.S.C. § 133 (exten	INO ACID SEQUENCE Does not the time period set the Office	SISCLOSURES action to which the Notice is	attached to
The nucleotide and/or amino acid sequence disclor for such a disclosure as set forth in 37 C.F.R. 1.82	osure contained in this applicat	on does not comply with the	, ,
 This application clearly fails to comply with the directed to the final rulemaking notice published the effective filing date is on or after July 1, 19 1998) and 1211 OG 82 (June 23, 1998). 	ed at 55 FR 18230 (May 1, 199	0), and 1114 OG 29 (May 15	5, 1990). If
2. This application does not contain, as a sepa required by 37 C.F.R. 1.821(c).	arate part of the disclosure on p	paper copy, a "Sequence Lis	ting" as
3. A copy of the "Sequence Listing" in compute 37 C.F.R. 1.821(e).	er readable form has not been	submitted as required by	
4. A copy of the "Sequence Listing" in compute computer readable form does not comply with attached copy of the marked -up "Raw Sequence of the marked representation.	the requirements of 37 C.F.R.		
5. The computer readable form that has been unreadable as indicated on the attached CRF submitted as required by 37 C.F.R. 1.825(d).			
☐ 6. The paper copy of the "Sequence Listing" is	not the same as the compute	r readable from of the "Sequ	ence Listing'

Applicant Must Provide:

7. Other:

as required by 37 C.F.R. 1.821(e).

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

Patentin Software Program Support

Technical Assistance......703-287-0200

To Purchase Patentin Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY